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Abstract: Nanoparticles have been investigated as drug carriers, because they provide a 
great opportunity due to their advantageous features: (i) various formulations using 
organic/inorganic materials, (ii) easy modification of targeting molecules, drugs or other 
molecules on them, (iii) effective delivery to target sites, resulting in high therapeutic 
efficacy and (iv) controlling drug release by external/internal stimuli. Because of these 
features, therapeutic efficacy can be improved and unwanted side effects can be reduced. 
Theranostic nanoparticles have been developed by incorporating imaging agents in drug 
carriers as all-in-one system, which makes it possible to diagnose and treat cancer by 
monitoring drug delivery behavior simultaneously. Recently, stimuli-responsive, 
activatable nanomaterials are being applied that are capable of producing chemical or 
physical changes by external stimuli. By using these nanoparticles, multiple tasks can be 
carried out simultaneously, e.g., early and accurate diagnosis, efficient cataloguing of 
patient groups of personalized therapy and real-time monitoring of disease progress. In this 
paper, we describe various types of nanoparticles for drug delivery systems, as well as 
theranostic systems. 
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1. Introduction  
Since polyalkylcyanoacrylate nanoparticles attached with anticancer drugs were described in the 
late 1970s, nanotechnology has been an emerging field in drug-delivery research, which aims to design 
drug carriers that deliver drugs more precisely to tumor cells and maintain them at a therapeutic 
concentration over a long period [1,2]. Nanocarriers for drug delivery are referred to as  
drug-incorporated macromolecular soft matrixes or inorganic solid, colloidal particles within a size of 
10–1000 nm, which is similar to that of biological macromolecules, such as proteins and DNA [3]. 
Because nanocarriers can be precisely fabricated with proper size, shape, surface charge, stability and 
various other characteristics for in vivo applications, nanocarrier-based drug delivery has been most 
extensively explored [4]. To further enhance their functionality, additional techniques, such as surface 
modifications, e.g., introducing a targeting moiety, are basically included in these approaches. For 
effective anticancer treatment, the drug must penetrate the tissue efficiently. Thus, studies suggested 
strategies to improve drug penetration through tumor tissue to enhance the therapeutic index by 
considering several delivery system on the basis of their abilities to penetrate tissue with an 
understanding of the physiological aspects of cancer [5]. For example, the vascular architecture around 
cancer is known to be poorly organized with reduced vascular density, irregular blood flow and 
compression of blood and lymphatic vessels by cancer cells [5]. In addition, numerous discoveries of 
biomolecular markers that are specifically expressed in cancer have been reported, which improved the 
understanding of cancer and resulted in targeted cancer therapies [6]. On the basis of these aspects, 
clinical approaches with nanotechnology have proven that drug delivery systems can show enhanced 
efficacy, while simultaneously reducing side effects, owing to properties, such as improved targeted 
delivery to tumors and active cellular uptake [7]. This review introduces drug delivery systems using 
nanotechnology, including general preparation of drug nanocarriers, strategies for their accumulation 
into cancer cells and recent advances in cancer therapy. 
2. Common Nanostructures for Drug Carriers: Their Structures and Drug-Loading Principles 
2.1. Supramolecular Organic Architectures 
2.1.1. Polymeric Micelles 
A polymeric micelle structure, consisting of a hydrophilic shell and a hydrophobic core, is 
commonly adapted in drug delivery systems, due to its tunable size and surface functionality, high 
monodispersity and excellent stability [8]. The polymers used for micelles range from simple natural 
polymers to exquisite synthetic copolymers, which have a generally amphiphilic characteristic. With 
regard to the drug-loading principles using this amphiphilic micelle structure, there are two typical 
routes: drug conjugation and drug encapsulation. Drug conjugation utilizes a non-water soluble drug as 
a hydrophobic core of the micelle, which is conjugated to the hydrophilic polymer backbone. For drug 
release, biodegradable chemical linkers are usually selected for conjugating the drug to the main chain. 
For example, Duncan et al. studied poly(ethylene glycol) (PEG)-doxorubicin (DOX) conjugates with 
peptide linkers. Their study covered several factors for drug delivery, e.g., drug release profiles, in vitro 
cytotoxicity and biodistribution, with regard to PEG-DOX polymers of linear or branched architecture 
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(molecular weight 5000–20,000 g/mol) and with different peptidyl linkers (GFLG, GLFG, GLG, 
GGRR and RGLG) (Figure 1) [9]. The second route is drug encapsulation, i.e., drug-loading micelles 
are formed by emulsion of the drug with ready-made amphiphilic copolymers. In this case, drugs are 
physically entrapped into the hydrophobic core of micelles. Poly(lactic-co-glycolic acid) (PLGA) is 
one of most popular hydrophobic polymers used as a core part for drug encapsulation [10]. PLGA has 
ester bonds that break down in the body, resulting in sustained drug release. Consequently, many 
researchers presented natural polymer-PLGA as biodegradable amphiphilic copolymer, e.g., 
hyaluronan-PLGA, dextran-PLGA, heparin-PLGA and chitosan-PLGA [11–13]. Some studies used a 
multi-benzene ring moiety as the hydrophobic core. When the drug has also many benzene rings, pi-pi 
interactions between the drug and micelles can affect drug loading and release profiles [14]. The 
physicochemical properties of amphiphilic polymers for drug-encapsulated micelles determine the 
factors that influence the drug delivery features in a similar manner, as chemical linkers do in  
drug-conjugated micelles. In addition, Abraxane is an albumin-bound form of paclitaxel with a mean 
particle size of approximately 130 nm as an anti-cancer chemotherapy drug that paclitaxel exists in a 
non-crystalline, amorphous state. It appears to provide greater access of the drug from the bloodstream 
to the tumor tissue and permits a higher dose of drug with a decreased infusion time [15–17].  
Figure 1. (a) Structure and (b) composition of the poly(ethylene glycol)  
(PEG)-peptide-doxorubicin (DOX) conjugates. Release of DOX from PEG-peptide-DOX 
conjugates during incubation with isolated rat liver lysosomal enzymes (tritosomes). 
Reproduced from [9] with permission of [American Chemical Society Publications]. 
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2.1.2. Bilayer Vesicles 
Some lipids and linear block copolymers with a particular hydrophilic/hydrophobic ratio can  
self-assemble to form vesicles, liposomes and polymersomes. These vesicles are closed bilayers whose 
core parts comprise the same solvent as that on the surface of the vesicles. Therefore, these vesicles are 
suitable to deliver water-soluble drugs or biomaterials, including enzymes, antibodies or genes [18,19].  
Panchagnula et al. reported that polyethylene glycol-coated liposomes encapsulating water-soluble 
prodrugs were successfully prepared to overcome their physical instability. They used rat plasma in an 
in vitro hydrolysis study and showed that the chemical bonds in the prodrug of paclitaxel were quite 
stable; the liposomes were also stable, and crystallization of paclitaxel was not observed [20].  
In addition, bilayer vesicles can be applied for the co-delivery of hydrophilic and hydrophobic 
therapeutic agents for cancer treatment. It has been demonstrated that polymersomes prepared by using 
PEG-PLA block-copolymers could be loaded with hydrophobic DOX in their shell and hydrophilic 
anti-Bcl-2 siRNA in their core. These drug/gene co-loading polymersomes showed high loading 
efficiency and excellent stability that originated from the polymeric core-shell structures with tunable 
void size and shell thickness and significant rigidity compared to liposomes. Co-delivery of 
drugs/genes using polymersomes inhibited the growth of cancer cells with much lower IC50 values, 
suggesting that this system can successfully reduce the side effects of cancer chemotherapy [21]. 
Liposome delivery systems offer the potential to enhance the therapeutic index of anticancer drugs, 
either by increasing the drug concentration in tumor cells. Among them, Myocet and Doxil were the 
first-approved liposome-based drugs for cancer treatments. Both products have longer circulating  
half-life in blood as compared with the free drug, but Doxil has a much longer circulation time in 
blood than Myocet [22,23].  
2.1.3. Cross-Linked Nanogels 
Nanogels are another type of polymeric nanostructure for drug delivery systems that is physically or 
chemically a cross-linked polymer network in nano-size [24,25]. Nanogels meet the requirements for 
drug carriers, e.g., high loading capacity, high stability and stimuli-responsive release characteristics 
for controlled delivery. Drug-loading approaches using nanogels are quiet similar to those of micelles, 
i.e., conjugation or hydrophobic interactions between the drugs and the nanogel matrix. A main 
concern in drug delivery using nanogels is to establish cross-linking, which is important to control 
their drug loading and release characteristics. The degree of cross-linking determines the pore size and 
swelling property of the nanogel, which is related to drug entrapment and release. Stenzel et al. 
reported that drug carriers prepared by using poly(polyethylene glycol methyl ether methacrylate)-
block-poly(5'-O-methacryloyluridine) (PPEGMEMA30-b-PMAU80) with a disulfide cross-linking 
agent, (bis(2-methacryloyloxyethyl)disulfide) showed increased drug loading capacity with increasing 
cross-linking degree (Figure 2). Disulfide cross-linkers are expected to react with redox species in the 
cells, e.g., glutathione and dithiothreitol, resulting in environment-specific release profiles [26]. The 
selection of the cross-linking moiety determines stimuli-responsive release characteristics for 
controlled delivery; common classification for cross-linkers includes disulfide, reactive amine,  
click-chemicals for host-guest interaction and photo-reactive chemicals with double bonds [24]. 
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Figure 2. (a) Synthesis and Degradation of Core-Cross-Linked Micelles and (b) TEM 
images of (top) block copolymer PPEGMEMA30-b-PMAU80, (middle) core-cross-linked 
micelles PPEGMEMA30-b-PMAU80-b-PDSDMA2*45, (bottom) PPEGMEMA30-b-
PMAU80-b-PDSDMA2*45 after reduction with DTT, using phosphotungstic acid staining. 
Reproduced from [26] with permission of [American Chemical Society Publications]. 
 
2.1.4. Solid Lipid Nanoparticles 
Solid lipid nanoparticles (SLNs) have been utilized as novel approach to drug delivery systems with 
spherical shape with an average diameter between 10 and 1000 nm. SLNs combine the advantages of 
lipid emulsion and polymeric nanoparticle systems, which possess a solid lipid core matrix stabilized 
by surfactants to solubilize liphophilic molecules [27–33]. They have potential advantages, such as the 
low toxicity and excellent physical stability, and can stably deliver liphophilic drugs with high loading 
capacity, while they cause toxic effects because of slow degradation. Therefore, drug release  
can be controlled released depending on lipid matrix incorporation [28,29]. Choi et al. developed 
doxorubicin-loaded solid lipid nanoparticles (SLN-DOX) using biocompatible compounds and 
examined their in vivo therapeutic effects. Compared with free DOX, SLN-DOX have the potential to 
serve as a useful therapeutic approach to overcome the chemoresistance of adriamycin-resistant  
breast cancer [33].  
2.2. Inorganic Cargoes: Simple Particles, Porous Materials, Hollow Structures 
2.2.1. Simple Sphere Nanoparticles 
Inorganic nanoparticles, such as gold nanoparticles (AuNPs), can be attractive cargoes for delivery 
of drugs, genes and proteins, because of their tunable parameters, e.g., particle size, surface properties 
and biocompatibility with low toxicity [34,35]. In particular, gold nanoparticles are remarkable drug 
carriers, because they can provide unique drug release strategies using internal or external stimuli, such 
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as glutathione, pH, heat and light [36,37]. To load drugs on inorganic nanoparticles, they are usually 
attached to the surface of inorganic nanoparticles by conjugation, charge interaction or hydrophobic 
interaction [38–40]. In particular, attaching the drug to the surface of inorganic nanoparticles is 
facilitated by thiol groups that are well known for their remarkable interaction with several inorganic 
nanoparticles, such as gold nanoparticles (Figure 3) [38]. In case of peptide delivery, additional 
cysteine moieties, which contain thiol groups, are introduced to peptide sequences for coating of the 
nanoparticles [41]. When charge interaction has to be applied, molecular coating of the surface with 
opposite charge precedes attachment via thiol groups [39]. Additional histidine moieties are also 
assumed to be an attractive tag to the metal to load the desirable drug/biomolecules [42]. 
Figure 3. (a) Synthesis of polyvalent RNA gold nanoparticle (AuNP) conjugates and  
(b) reaction strategy showing the successive steps for the construction of NTA-terminated 
nanoparticles for specific immobilization of histidine-tagged proteins. Reproduced  
from [38,42] with permission of [American Chemical Society Publications]. 
 
 
2.2.2. Porous Nanoparticles  
Since mesoporous silica nanoparticles were first reported (MCM-41) for use as drug delivery 
system in 2001, several remarkable reports have been published using silica-based porous materials, 
e.g., SBA-15 or MCM-48, as drug carriers [43]. Mesoporous silica nanoparticles have ordered uniform 
pores for precise control of drug loading and releasing. Their high surface area is also an attractive 
characteristic for their use as drug carriers, because drugs are usually loaded onto the pore surface by 
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physical adsorption. Drug loading capacity and release profiles can be very different depending on 
pore diameter, pore topology, surface properties, etc. [44]. Andersson et al. reported additional factors 
related to the porosity and kinetic release. They demonstrated the effects of pore connectivity, 
geometry and matrix degradation in aqueous media, as well [45]. Considering these tunable factors, 
mesoporous silica nanoparticles were used to deliver a variety of guest molecules, including drugs, 
such as ibuprofen, doxorubicin (DOX) and cisplatin, therapeutic genes and antibodies [44–48].  
Furthermore, the payload molecular stored within these pore domains of mesoporous silica 
nanoparticles through chemical modification that silica nanoparticles could stimulus-responsively 
mechanically interlock molecules, mechanized silica nanoparticles. These nanoparticles either change 
shape or shed off their parts in response to a specific stimulus, such as changes in redox potential, 
alterations in pH, irradiation with light or oscillating magnetic field, allowing payload molecules to 
release from the nanopores to a precise location at the appropriate time [49]. Luminescent porous 
silicon nanoparticles were developed, which are able to carry a drug payload and monitor their 
accumulation and degradation in vivo by intrinsic near-infrared photoluminescence. In addition, these 
particles could self-destruct into renally cleared components relatively fast, thus it showed  
low-toxicity [50].  
2.2.3. Hollow Nanoparticles 
Hollow inorganic nanoparticles represent a unique structure for drug containers. To produce a 
cavity in the nanoparticle, removable templates are introduced, e.g., polymeric or rather-soft inorganic 
nanoparticles. Hollow silica nanoparticles, extensively used as drug carrier, have been reported using 
various templates, including PS−PVP−PEO block copolymer [51], Fe3O4 clusters [52], and so forth. 
After silica coating of the templates, the following steps are required for proper removing of the 
template: dissolution using apt solvents [53] or calcination [51,53] for organic templates and acidic 
etching for soft inorganic templates [52]. Haam et al. reported high drug loading efficiency and 
sustained release kinetics of a model drug (DOX) using hollow silica nanoparticles with Fe3O4 clusters 
as template (Figure 4) [52]. On the other hand, Xia et al. reported silver-template hollow gold 
nanocages with controllable void size, wall thickness and wall porosity by employing an elaborate 
process of galvanic replacement, alloying and dealloying. With this hollow gold nanocage as the 
potential drug carrier, they developed a drug delivery system for controlled release with near-infrared 
light, which takes advantage of the unique optical property of gold in nanoscale, i.e., surface  
plasmon resonance [54]. 
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Figure 4. (a) Schematic illustration of drug-loaded hollow silica nanoparticles for drug 
delivery vehicles; (b) three types of hollow silica nanoparticles (HSNPs) as drug delivery 
vehicles: (A) HSNPs-OH, (B) HSNPs-NH2 and (C) HSNPs-PEG; (c) DOX release profiles 
and semilogarithmic plot of DOX release of HSNPs (●), HSNPs-NH2 (▲) and HSNPs-PEG 
(■). Reproduced from [52] with permission of [American Chemical Society Publications]. 
 
2.3. Hierarchical Organic/Inorganic Hybrids 
To deliver two or more therapeutic agents, organic/inorganic hybrids can be applied as the drug 
delivery carrier [55]. Inorganic nanoshells with a polymer core matrix were prepared to deliver 
therapeutic antibodies and anticancer drugs. In this study, the anticancer drug DOX was incorporated 
in biodegradable PLGA nanoparticles by applying the nanoemulsion method using poly vinyl alcohol 
as the amphiphilic polymer (Figure 5a). After gold shell coating on the DOX-loaded PLGA 
nanoparticles, cetuximab, which is a therapeutic antibody for the epithermal growth factor receptor, 
was conjugated onto the gold nanoshell surface using functionalized PEG as the cross-linker [56]. In 
addition, porous silica nanoparticles coated with a cationic polymer were used for co-delivery of an 
anticancer drug and therapeutic gene. In this report, DOX was adsorbed onto mesoporous silica 
nanoparticles, as described above. In another study, mesoporous silica nanoparticles were coated with 
G2 amine-terminated poly(amido amine) (PAMAM) dendrimers to load anti-Bcl-2 siRNA as a 
therapeutic gene by charge-charge interaction (Figure 5b) [57]. The drug loading principles for these 
organic/inorganic hybrids obey those of each system to which the respective drug belongs. However, 
the drug release pattern of hybrids could be quiet different to those of a separated system, because the 
local environment in the hybrid structure could alter the drug. A highly charged G2 amine-terminated 
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PAMAM dendrimer layer can act as a barrier against the diffusion of hydrophobic DOX from the core 
of mesoporous silica nanoparticles. 
Figure 5. (a) Schematic illustration of multifunctional drug-loaded gold nanoshells for 
synergistic cancer therapy; (b) schematic diagram of a co-delivery system based on 
mesoporous silica nanoparticles (MSNs) to deliver DOX and Bcl-2-targeted siRNA 
simultaneously. Reproduced from [56,57] with permission of [Willey]. 
 
3. Enhanced Drug Accumulation at Target Sites: Pharmacokinetics and Biodistribution 
3.1. General Physiological Strategies: Size Modulation for Enhanced Circulation Half-Life, 
Reticuloendothelial system (RES) Avoidance by Surface Modification (PEG) 
Drug delivery carriers remain in the circulation via the reticuloendothelial system (RES), e.g., liver 
and spleen, depending on their size and surface characteristics. To overcome their drawbacks, various 
parameters, including size and surface modification, have been studied. Among surface modification 
strategies, PEG as hydrophilic polymers can increase the half-life due to their high water solubility by 
hydrogen bonding between their oxygen atoms and water, as well as they can reduce the uptake by the 
RES through protection against degrading enzymes [58,59]. PEG-modified polymers have been 
researched for effective drug delivery. Kataoka used PEG-containing block copolymer micelles as 
drug-delivery carriers that led to the development of dendritic and star-shaped amphiphilic structures, 
which exhibit enhanced control over architecture, size and surface functionality of micelles compared 
to linear block copolymers.  
3.2. Cancer-Specific Physiological Strategies  
3.2.1. Passive Targeting by EPR Effects  
Tumors can present an increased production of several mediators and enzymes, which altogether 
enhance the permeability of tumor vessels with respect to those of normal tissues, because of the rapid 
vascularization. In addition, little or no lymphatic drainage in tumors leads to passive accumulation 
and retention of nanoparticles with prolonged circulation times in the tumor resulting in an enhanced 
permeation and retentions (EPR) effect [60–64]. In order to reach the target solid tumor site, the 
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circulation time of drug carriers in the blood should be increased, which can be achieved by 
incorporating well-characterized macromolecules, e.g., PEG, polyacrylic acid, polyvinyl alcohol, 
dextran, chitosan and polyethyleneimine. DOX, as an anticancer drug, incorporated into PEG-coated 
liposomes, is currently in use on clinical conditions and demonstrated high efficacy in EPR-based 
tumor therapy with low side effects [60]. Haam et al. developed PEG-modified drug carriers for 
reducing toxicity and increasing circulation time [65–67]. These carriers effectively delivered the 
drugs to tumor cells and showed high therapeutic effects.  
3.2.2. Active Targeting by Molecular Binding Receptor (Antibody, Targetable Polymer, etc.)  
Selectively delivering drugs to target tumors can serve to improve the therapeutic efficiency in 
cancer treatment, while reducing side effects in normal tissues. Drug delivery carriers that are modified 
by specific surface markers (targeting moieties) enable their specific recognition by target cells, which 
facilitates effective delivery to target tumor tissues [68–73]. As targeting moieties, antibodies, peptides 
(arginine-glycine-aspartate; RGD), nucleic acids (aptamers), polysaccharides (hyaluronic acid [HA]), 
glycoproteins (transferrin) and small molecules (folate) are extensively employed [11,14,65,66,69–85]. 
For example, Haam et al. developed anti-HER2/neu antibody (Herceptin
®
; HER)-modified drug 
carriers for effective therapy of HER2/neu receptor overexpressing breast cancer [14,67]. This carrier 
showed synergistic therapeutic effects of DOX and HER as a therapeutic antibody by suppressing the 
cell growth signals on the HER2/neu receptor, which led to more effective tumor growth inhibition 
compared to control groups, resulting from target-specific delivery to tumor sites through  
receptor-mediated endocytosis (Figure 6). Especially, DOX are released form the pyrenyl groups of 
the polymer in an acidic condition owing to decreased in π–π interactions between DOX and the 
pyrenyl groups (Figure 6c). From in vivo results, these particles were confirmed excellent synergistic 
therapeutic efficacy (Figure 6b,d). In addition, hyaluronic (HA)-coated drug carriers (HCDs) were 
successfully synthesized for targeted delivery of DOX to CD44-expressing human breast cancer cells. 
Because of its solubility in aqueous solutions, HA could strongly interact with the CD44 receptor and 
demonstrated increased half-life in the body. It has been reported that HCDs have therapeutic 
potentials in cancer treatment by increasing the tumoricidal efficacy on target cancer cells, while 
reducing their cytotoxicity to non-targeted cells in order to minimize the side effects [74].  
Aptamer-conjugated polyplexes (APs) were developed containing shRNAs against Bcl-xL and DOX 
in combination cancer therapy. These APs demonstrated synergistic and selective cancer cell death 
through AP-mediated co-delivery of very small amounts of DOX- and Bcl-xL-specific shRNAs by an 
intrinsic apoptotic pathway [77]. Recently, Ruoslahti et al. reported that tumor-homing peptide 
(iRGD)-mediated compounds were delivered into the tumor parenchyma that allow significant 
improvement of the sensitivity of imaging agents and enhance the activity of therapeutic  
agents [76–82]. 
3.2.3. Active Targeting by Magnetic Guidance  
Therapeutic delivery by magnetic guidance is an effective strategy for the selective delivery to 
target sites with drug release control. In this case, drug delivery carriers containing magnetic 
nanoparticles have been utilized, in which magnetic particles were guided along an externally placed 
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magnet, and thus, drug in company of magnetic nanoparticles could be delivered to the desired site. 
Therefore, this approach achieved significantly high localization and retention in the target region with 
low unwanted effects of chemotherapy [64,86–88]. Gang et al. prepared magnetic polymeric 
nanoparticles, magnetic PCL nanoparticles, containing an anticancer drug (gemcitabine) to develop a 
more efficient drug delivery system for cancer therapy [89]. The magnetic PCL nanoparticles showed 
high therapeutic effects by delivering drugs efficiently to magnetically targeted tumor tissues; in 
addition, they could be used as magnetic resonance (MR) probes to detect cancer. This system could 
be applied for targeted therapy with cancer detection. 
Figure 6. Schematic illustration of (a) multifunctional magneto-polymeric nanohybrids 
(MMPNs) and (c) Herceptin-modified pH-sensitive drug-delivering magnetic nanoparticles 
(HER-DMNPs) for cancer therapy, respectively. Comparative therapeutic efficacy study of 
MMPNs (b) and HER-DMNPs (d) in the in vivo model. Reproduced from [14,70] with 
permission of [Willey].  
  
4. Ongoing Advances in Drug Delivery Systems 
4.1. Stimuli-Responsive Drug Delivery 
Stimuli responsive drug delivery systems are investigated for remotely controlled drug  
release by specific external or internal stimuli, including light [89–94], magnetic field [95–102],  
ultrasound [103–109], pH [100–114] and specific enzymes’ activity [115,116]. These systems allow 
the drug concentration to be maintained within its therapeutic window to target sites and to release the 
drug by changing the structures of their components.  
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4.1.1. Light-responsive Drug Delivery Systems  
Light as an external stimulus causes structure and temperature changes in systems, which can be 
used for the spatiotemporal control of drug release. Drug delivery systems with light-activated 
materials have been designed using various strategies, e.g., drugs conjugated with nanoparticles via 
photo-cleavable ligands. After light-irradiation, the drug can be trigger-released by cleaving or 
activating its linkage [89–92]. Lu et al. developed nanoimpeller-based delivery systems, light-activated 
meso-structured silica particles containing molecular impellers, could regulated the drug release inside 
of living cell by remotely controlling both light intensity and the irradiation time (Figure 7) [93].  
Figure 7. (a) Designed pore interiors of the light-activated mesostructured silica (LAMS) 
nanoparticles functionalized with azobenzene derivatives; (b) Time-dependent release of 
Rhodamine B dye from the LAMS into water. The arrow indicates the time at which the 
azobenzene activation light was turned on; (c) Confocal microscopy images of the 
photocontrolled staining of PANC-1 cancer cells. Propidium iodide (PI)-loaded LAMS was 
incubated with the cells for 3 h in the dark. The cells were then exposed to the activation 
beam for 1 to 5 min. After further incubation in the dark for 10 min, the cells were 
examined with confocal microscopy (λex = 337 nm). PANC-1 cancer cells incubated with 
the PI-loaded LAMS and illuminated for 0 (i), 1 (ii), 3 (iv) or 5 min (vi) under a  
constant = 0.2 W cm
2
, 413 nm light or with different light intensities (=0.01 (iii)  
or =0.1 W cm
2
) (v) for 5 min with a 413 nm light. Scale bar = 30 μm. Reproduced  
from [93] with permission of [Willey]. 
 
In addition, drug loaded onto nanoparticles can be released from the polymeric matrix to the outside 
layer through diffusion by temperature change. This is possible due to the hydrogen bonding among 
polymer networks that become weak as the temperature increases [94].  
Recently, Haam et al. developed a novel nanotherapeutic system consisting of a PLGA matrix 
containing DOX as a chemotherapeutic agent and a gold over-layer on a polymer matrix capable of 
exhibiting a photothermal effect [56]. Upon light (near-infrared) irradiation, DOX can be abruptly 
released from the polymer matrix for high cancer cell toxicity, and photothermal therapy can be 
applied by using the heat from the gold shell. In addition, drugs were conjugated with drug delivery 
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systems via light-activated ligands, which can be used for controlled released using external light 
irradiation by activating cleavage of its specific ligands, e.g., o-nitrobenzyl linkage [90]. 
4.1.2. Magnetically-Triggered Drug Delivery Systems  
Magnetic nanoparticles produce heat through various energy losses under an external alternating 
magnetic field because of the transformation of their magnetic energy into heat by the dynamic 
response of a dipole with their magnetic moments [95–98]. Hyperthermia by magnetic field causes 
cancer destruction by activating cell-death signaling. Magnetic nanoparticles are not only magnetically 
hyperthermic, but they are also drug delivery or actuators capable of controlled drug release [99–102]. 
Recently, Cheon et al. developed an on-demand drug delivery/release system as a magnetothermally 
responsive system for highly effective in vivo cancer treatment. This system showed a high tumor 
suppression effect with low drug dosage compared to before (Figure 8) [99–101]. 
Figure 8. (a) Illustration of synthetic route of magnetically activated release system 
(MARS) nanoparticles. ZnNCs (1) are synthetically positioned at the core of the 
mesoporous silica nanoparticles (2). The base of the molecular machine is then attached to 
the nanoparticle surface (3). Drug is loaded into the particle and capped (4) to complete the 
system. Release can be realized using remote heating via the introduction of an oscillating 
magnetic field (5). The particles and machines are not drawn to scale. Cargo is released 
using magnetic actuation; In (b), the MARS nanoparticles were continuously exposed to 
the magnetic field. The inset shows the data as a release profile; In (c), a sample was kept 
at 0 °C and exposed to pulses of the magnetic field. A single AC magnetic field exposure 
(●) exhibited ~40% cargo release after an initial 1 min pulse. Multiple pulses performed at 
1, 3, 5, 7 and 9 min and then every 20 min for 270 min (■) enabled more dye release until 
all of the dye diffused out. A baseline (▲) was obtained by monitoring the fluorescence 
with no pulses. The low temperature of the surrounding solution (0 °C) was maintained in 
order to observe the effects only from the magnetic field and not from heating of the 
surrounding solution. Reproduced from [101] with permission of [Willey]. 
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4.1.3. Ultrasound-Mediated Drug Delivery Systems 
It has been reported that the interaction of ultrasound with nanoparticles could enhance drug 
delivery in tumors cells, because this affects the properties of tumor vasculature and cell membrane 
and induces non-thermal effects by nanoparticle oscillation and acoustic streaming. This interaction 
allows enhancement of drug delivery [103–109]. Ultrasound-absorbed nanoparticles could control the 
drug-releasing behavior of nanoparticles and their distribution. In addition, ultrasound has practical 
advantages in therapeutic usage, because of clinical accessibility, low cost and safety.  
4.1.4. pH-Responsive Drug Delivery Systems 
Cancer cells produce more lactic acid than normal cells by increased glycolysis and proton-pump 
activity; the acid is released to extracellular regions, leading to a lower extracellular pH (pH 6.5 to 7.2) 
than blood and normal tissues (pH 7.4). On the basis of this feature, pH-responsive drug carriers have 
been actively developed to facilitate specific responses to cancer cells without activation under normal 
physiological conditions [110–114]. Recently organic/inorganic nanoparticles containing aromatic 
molecules were investigated, of which the π (pi)–π (pi) interaction was affected by ionization due to 
pH changes that resulted in drug release [14]. Moreover, novel pH-sensitive nanosphere designed for 
colon-specific delivery were prepared using polymeric mixtures of poly(lactic-co-glycolic) acid (PLGA) 
and a pH-sensitive methacrylate copolymer, and this nanosphere showed strongly pH-dependent drug 
release properties in acidic condition and particulate targeting ability against specific colon cells in 
inflammatory bowel disease [111].  
4.1.5. Enzyme-Responsive Drug Delivery Systems  
Recently, drugs conjugated with nanoparticles via peptide linkers enable triggered release by 
specific enzymatic activation, in, which a specific peptide sequence is hydrolyzed or cleaved  
in the presence of specific enzymes (cathepsin B, caspase) or protein antigens, e.g., matrix 
metalloproteinases [115,116]. 
4.2. Theranostic Nanoparticles 
Nanoparticles have been developed in combination with myriad payload drugs, imaging agents and 
targeting moieties, leading to the formulation of theranostic nanoparticles capable of delivering 
therapy concomitant with diagnosis. Co-localization of the MR image (MRI) detection site and drug 
release site ensures increased anticancer treatment efficacy; thus, this system allows early and  
accurate diagnosis, efficient cataloguing of patient groups for personalized cancer therapy and  
real-time monitoring of disease progress (Figure 9) [117–128]. Haam et al. developed multifunctional  
magneto-polymeric nanohybrids composed of magnetic nanocrystals and anticancer drugs 
encapsulated by an amphiphilic block copolymer. The antibody-modified nanohybrids exhibited 
ultrasensitive targeted detection by MRI with excellent synergistic effects on tumor growth inhibition 
(Figure 6a,b) [70]. Brody et al. also synthesized polyacrylamide-based hydrogel particles containing a 
PET imaging probe as the theranostic carrier against lung cancer [128]. These studies demonstrated 
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that this approach could be used as a novel nanodrug delivery system for the simultaneous diagnosis 
and treatment of various types of cancers.  
Figure 9. Magnetic nanoparticle (MNP) possessing various ligands to enable 
multifunctionality from a single nanoparticle platform. Reproduced from [92] with 
permission of [Elsevier]. 
 
In particular, the application of these emerging systems in personalized therapy requires the 
development of stimuli-responsive, activatable nanomaterials that are capable of producing chemical 
or physical changes in vivo. In addition, they need to be able to respond appropriately to subtle in vivo 
changes for the controlled release of the therapeutic content, to obtain information on the metabolism 
and to be activated at an appropriate time for therapy and signal induction. Therefore, activatable 
nanomaterial-based therapies generating only localized effects are intrinsically less invasive than 
conventional therapies, such as surgery and nonspecific drug delivery. They are expected to increase 
the efficacy of therapeutic agents, while reducing unwanted side effects, such as toxicity. In addition, 
they could greatly curb the systemic side effect of anticancer drugs by regulating drug release  
kinetics [11,14,129–133]. 
Notably, activatable theranostic nanoparticles could be effective in cancer therapy in that the loss of 
drug is minimized until the target is known to exist in the patient, as well as in monitoring and 
verifying that the target has been reached and that the therapy is working. Recently, pH-activatable 
theranostic agents were developed, in which organic-soluble anticancer drugs can be trapped along 
with magnetic nanoparticles inside an amphiphilic polymer that delivers anticancer drugs to cancer 
cells and effectively labels tumors for MRI [14]. The extracellular pH of tumors is more acidic  
(pH 5–6) than blood and normal tissues (pH 7.4), because of the unique microenvironment of tumors, 
i.e., lactic acid is produced by tumors and released to extracellular regions. This fact has been actively 
exploited to develop drug carriers that can specifically respond to cancer cells with low pH values 
while remaining inactive at normal physiological conditions (Figure 6c,d) [134]. The drug release 
profiles of these pH-responsive drug carriers can be understood as a function of the pH value. Thus, 
the additional pH-responsive function of theranostic nanocarriers could give rise to a potent,  
multi-tasking, all-in-one system for cancer therapy. In this method, the drug delivery site coincides 
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with the MRI detection site. Furthermore, upon reaching the target site, the drug release profile, which 
can be used to estimate the amount and release duration of the delivered drug, can be closely 
monitored to assess treatment efficacy. These properties could greatly aid in the decision-making 
process for patient-specific drug administration strategies, moving closer to the full implementation of 
effective cancer therapy, which would generate innovations and play a critical in nanomedicine [14].  
5. Conclusion 
In the past decades, the use of nanotechnology for drug delivery systems has grown exponentially. 
On the basis of considerable advances in the fabrication of drug nanocarriers with organic and/or 
inorganic architecture, worldwide pre-clinical researches have been underway with the current 
understanding of cancer, which undoubtedly expanded more than ever before. This review focused on 
drug delivery systems in cancer treatment using nanotechnology, providing an overview of the 
physicochemical principles of fine delivery systems targeted for cancer and cancer environments, 
whose pathophysiological characteristics are the strategic gateway for efficient nanoscale therapy. 
Ongoing developments have further expanded the boundary of this paradigm in medicine, such as the 
concept of “theranosis”, a system that can be used to perform diagnosis and therapy simultaneously. 
Although there have been toxicity and safety issues, we believe that we will benefit from the new 
knowledge of molecular events in cancer gathered by nanoscale drug delivery systems. With the 
continued discovery of new materials, the establishment of improved designs and considerate efforts 
for sophisticated optimization, we predict that a “cancer-overcoming era” will emerge. 
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